HOOKIPA Pharma Statistics
Total Valuation
HOOKIPA Pharma has a market cap or net worth of $21.46 million. The enterprise value is -$35.47 million.
Important Dates
The next estimated earnings date is Friday, March 21, 2025, before market open.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HOOKIPA Pharma has 12.05 million shares outstanding. The number of shares has increased by 44.53% in one year.
| Current Share Class | 9.66M |
| Shares Outstanding | 12.05M |
| Shares Change (YoY) | +44.53% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 27.67% |
| Float | 6.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.43 |
| Forward PS | n/a |
| PB Ratio | 0.30 |
| P/TBV Ratio | 0.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.26, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.26 |
| Quick Ratio | 2.97 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -897.10 |
Financial Efficiency
Return on equity (ROE) is -51.99% and return on invested capital (ROIC) is -32.96%.
| Return on Equity (ROE) | -51.99% |
| Return on Assets (ROA) | -20.89% |
| Return on Invested Capital (ROIC) | -32.96% |
| Return on Capital Employed (ROCE) | -56.37% |
| Revenue Per Employee | $279,324 |
| Profits Per Employee | -$242,296 |
| Employee Count | 179 |
| Asset Turnover | 0.37 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HOOKIPA Pharma has paid $164,000 in taxes.
| Income Tax | 164,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.23% in the last 52 weeks. The beta is 0.71, so HOOKIPA Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -73.23% |
| 50-Day Moving Average | 1.97 |
| 200-Day Moving Average | 4.49 |
| Relative Strength Index (RSI) | 41.23 |
| Average Volume (20 Days) | 44,725 |
Short Selling Information
The latest short interest is 91,497, so 0.76% of the outstanding shares have been sold short.
| Short Interest | 91,497 |
| Short Previous Month | 145,868 |
| Short % of Shares Out | 0.76% |
| Short % of Float | 1.32% |
| Short Ratio (days to cover) | 0.38 |
Income Statement
In the last 12 months, HOOKIPA Pharma had revenue of $50.00 million and -$43.37 million in losses. Loss per share was -$3.55.
| Revenue | 50.00M |
| Gross Profit | -25.30M |
| Operating Income | -45.75M |
| Pretax Income | -48.43M |
| Net Income | -43.37M |
| EBITDA | -42.42M |
| EBIT | -45.75M |
| Loss Per Share | -$3.55 |
Full Income StatementBalance Sheet
The company has $59.75 million in cash and $2.83 million in debt, giving a net cash position of $56.93 million or $4.72 per share.
| Cash & Cash Equivalents | 59.75M |
| Total Debt | 2.83M |
| Net Cash | 56.93M |
| Net Cash Per Share | $4.72 |
| Equity (Book Value) | 71.80M |
| Book Value Per Share | 5.96 |
| Working Capital | 64.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$67.26 million and capital expenditures -$614,000, giving a free cash flow of -$67.88 million.
| Operating Cash Flow | -67.26M |
| Capital Expenditures | -614,000 |
| Free Cash Flow | -67.88M |
| FCF Per Share | -$5.63 |
Full Cash Flow StatementMargins
Gross margin is -50.60%, with operating and profit margins of -91.51% and -86.74%.
| Gross Margin | -50.60% |
| Operating Margin | -91.51% |
| Pretax Margin | -86.42% |
| Profit Margin | -86.74% |
| EBITDA Margin | -84.84% |
| EBIT Margin | -91.51% |
| FCF Margin | n/a |
Dividends & Yields
HOOKIPA Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.53% |
| Shareholder Yield | -44.53% |
| Earnings Yield | -202.13% |
| FCF Yield | -316.34% |
Analyst Forecast
The average price target for HOOKIPA Pharma is $10.67, which is 499.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.67 |
| Price Target Difference | 499.44% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 0.22% |
| EPS Growth Forecast (5Y) | -23.10% |
Stock ForecastsStock Splits
The last stock split was on July 10, 2024. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Jul 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
HOOKIPA Pharma has an Altman Z-Score of -3.96 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.96 |
| Piotroski F-Score | 2 |